Use of non-transition metal coordinated dipyridoxyl compounds to prevent and treat chemotherapy-induced PSN

US10888553B2 · kind B2 · utility

Assignee

• KARLSSON-TUNER INVEST AS · NO

Inventors

• Jan-Olof Karlsson · Oslo, NO
• Per Jynge · Trondheim, NO
• Rolf Andersson · Vikingstad, SE

Key dates

• Filing date: Nov 13, 2017
• Grant date: Jan 12, 2021
• Expiry date: Nov 13, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There is disclosed a platinum ion chelating dipyridoxyl compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein the dipyridoxyl compound is uncoordinated or coordinated with a metal ion which is not a transition metal, for prevention or treatment of chemotherapy drug induced peripheral sensory neuropathy in a patient, wherein the chemotherapy drug comprises platinum ions. An example of such a chemotherapy drug is oxaliplatin. The drawbacks of previous metal complexed compounds containing manganese ions are eliminated. A more frequent use of the drug is possible since the problem in the prior art with accumulated manganese neurotoxicity is eliminated. The compounds can be administered both temporally and spatially separately from chemotherapy.